Harry H. Yoon

Also affiliated with WinnMed, Mayo Clinic in Arizona, Mayo Clinic in Florida

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.”.

Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4146

N/A

0.104DataRank · unranked

1 citations

Kian-Huat Lim, Robert R. McWilliams, Rama Suresh, A. Craig Lockhart, Amberly Brown +15 more

Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data

OncoTargets and Therapy(2021)10.2147/ott.s216047

N/A

0DataRank · unranked

19 citations

Harry H. Yoon, Lionel Aurelien Kankeu Fonkoua

Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?

Journal of Clinical Oncology(2023)10.1200/jco.23.01982

N/A

0DataRank · unranked

4 citations

Harry H. Yoon, Mojun Zhu